Company intelligence / Profile preview
HLB Genex
Seoul, South Koreahlb-group.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
HLB Genex is a South Korean biotechnology company and a subsidiary of the HLB Group, focused on the development of innovative therapies for cancer and neurodegenerative diseases. The company leverages its relationship with the broader HLB ecosystem to advance clinical-stage assets, including collaborations on VEGFR inhibitors and immunotherapy combinations. HLB Genex is particularly active in exploring gene and cell therapy applications to address high unmet medical needs in oncology. Its business model involves a mix of internal R&D and strategic partnerships to accelerate the commercialization of its pipeline candidates.
- Therapeutic areas
- NeurologyOncology
- Modalities
- Small moleculeGene therapyCell therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
HLB Life ScienceElevar Therapeutics
Beyond the preview
Go deeper on HLB Genex.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HLB Genex.